PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

As genetic and biomarker tests become more common, so do new therapies that target specific tumor types and may lead to ...

It would be short-sided, erroneous and dangerous to think ill of mifepristone, which has several important applications,, M.D ...

hypokalemia or QT prolongation – serious adverse events that can arise in patients taking currently approved medications – ...

Triple-positive breast cancer is a type of breast cancer that tests positive for estrogen receptors, progesterone receptors, and high levels of HER2 protein. Some types of breast cancer cells use ...

Corcept Therapeutics (CORT) announced that the FDA filed its New Drug Application (NDA) submission for its proprietary, selective cortisol ...

Patients who undergo a medication abortion during the first trimester of pregnancy are at a significantly higher risk of ...

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

For many women, finding out that they have breast cancer is the worst news they can receive. Even worse news is if the breast cancer is termed “triple-negative,” which is ...